

The Use of Lung Clearance Index to Assess Cystic Fibrosis–Related Lung Disease



Outline

- **The natural history of lung disease in CF and the use of FEV₁ vs LCI to assess pulmonary dysfunction**
 - The physiological underpinnings of lung disease in CF
 - The strengths and limitations of spirometry and multiple breath washout techniques to assess pulmonary dysfunction, and methods for determining LCI
- **LCI as an outcome measure in CF**
 - The use of LCI to discriminate between CF and health, to detect early lung disease and to track early disease progression
 - Correlation between LCI and data obtained with multiple imaging modalities
 - Relation between LCI, inflammatory markers, and pulmonary exacerbations
- **LCI as an outcome measure in CF clinical trials**
 - Clinical trial data from dornase alpha and hypertonic saline trials
 - Evaluating the clinical significance of LCI results


Background

FEV₁, LCI, and the Physiology of Early Lung Disease in CF



FEV₁: The Cornerstone of Pulmonary Function Testing

- FEV₁ is the volume of air forcefully expelled from the lungs in the first second
- It is the most widely used method for clinical monitoring of CF lung function
- FEV₁ provides a measure of total airway resistance
- It correlates best with airway wall thickness and mucus plugging, both features of larger airway obstruction



FEV₁: The Cornerstone of Pulmonary Function Testing (cont)

Strengths

- Widely used in the clinic and in clinical trials^{1,2}
- When expressed as percent predicted, FEV₁ is the most useful objective measure of pulmonary status³
- Validated prognostic indicator of lung disease progression and survival time in CF^{2,4}
- Recognized as a primary outcome by the FDA and EMA⁵

Limitations


- Not sensitive to small airway damage that occurs earlier in CF lung disease^{6,7}
- Not sensitive to mild lung disease^{6,7}
- FEV₁ values often do not correlate with more detailed assessments of pulmonary disease severity such as CT imaging^{8,9}
- Spirometry can be difficult for young children to perform¹⁰
- Spirometry measurements are dependent on patient cooperation and effort¹⁰

CT, computed tomography; FDA, Food and Drug Administration; EMA, European Medicines Agency.

1. De Benedictis FM, et al. *Eur J Clin Pharmacol.* 2010;67(Suppl 1):49-59. 2. Liou TG, et al. *Am J Epidemiol.* 2001;153(4):345-352. 3. Yankaskas JR, et al. *Chest.* 2004;125(1 Suppl):1S-39S. 4. Corey M. *Proc Am Thorac Soc.* 2007;4(4):334-337. 5. Kent L, et al. *J Cyst Fibros.* 2014;13(2):123-138. 6. Gustafsson PM, et al. *Thorax.* 2008;63(2):129-134. 7. Horsley A, Siddiqui S. *Respirology.* 2015;20(1):33-45. 8. Brody AS, et al. *J Pediatr.* 2004;145(1):32-38. 9. de Jong PA, et al. *Eur Respir J.* 2004;23(1):93-97. 10. Aurora P, et al. *Am J Respir Crit Care Med.* 2004;169(10):1152-1159.



Limitations to the Use of FEV₁




Spirometry is normally only used in patients aged 6 years or older. In infants spirometry often requires sedation² and can be difficult to perform in young children³

ppFEV₁, percent predicted forced expiratory volume in 1 second.

1. Cystic Fibrosis Canada. (2018). The Canadian Cystic Fibrosis Registry 2018 Annual Data Report 2. Linnane BM, et al. *Am J Respir Crit Care Med.* 2008;178(12):1238-1244. 3. Aurora P, et al. *Am J Respir Crit Care Med.* 2004;169:1152-1159.



Limitations to the Use of FEV₁ (cont)



FEV₁ is not sensitive to small airway damage that occurs early in disease^{2,3}
(small airways contribute ~10% of total airway resistance in healthy adults)³

Hence, in early CF, there can be considerable disturbance of large numbers of
small airways, with relatively little effect on FEV₁³


ppFEV₁, percent predicted forced expiratory volume in 1 second.

1. Cystic Fibrosis Canada. (2018). The Canadian Cystic Fibrosis Registry 2018 Annual Data Report. 2. Gustafsson PM, et al. *Thorax*. 2008;63(2):129-134. 3. Horsley A et al. *Respirology*. 2015;20(1):33-45.



“The ability to identify early airway dysfunction in these ‘silent years’, when FEV₁ is often within normal range, is of great importance for investigating new therapies in infants and young children and in those with mild disease”

LCI Is a Measurement of Lung Function Capable of Detecting Early Airway Disease in CF




Reprinted from *Respiratory Medicine*, 103(6), Horsley A, Lung clearance index in the assessment of airways disease, 793-799, Copyright 2009, with permission from Elsevier.

- LCI is a numerical value derived from multiple breath washout (MBW) test data
- LCI represents the number of breaths to reduce the tracer gas to a predefined concentration

LCI Detects Early Airway Disease in CF


Why more breaths are required to clear tracer gas from CF lungs



- LCI is an indication of ventilation heterogeneity, based on how many breaths it takes to wash a tracer gas out of the lungs during tidal breathing¹
- LCI is sensitive to damage in both large and small airways²
- LCI values increase with lung disease severity¹
- LCI can detect early lung disease before a noticeable drop in spirometry measurements occurs¹

1. Horsley A. *Respir Med*. 2009;103(6):793-799. 2. Verbanck S, et al. *J Appl Physiol*. 2012;112(5):782-790. 3. Horsley A, Siddiqui S. *Respirology*. 2015;20(1):33-45. The Human Respiratory System. In: Tu J, et al. *Computational Fluid and Particle Dynamics in the Human Respiratory System*. Springer, 2013; Ch. 2..

Performing an MBW Test^{1,2}




1. Horsley A. *Respir Med.* 2009;103(6):793-799. 2. Subbarao P, et al. *Ann Am Thorac Soc.* 2015;12(6):932-939.



Tracer Gas Selection

Nitrogen (N_2)



Wash-in

None (N_2 present in the lungs)¹


Washout

Subjects breathe 100% oxygen (O_2)¹

Limitation

In infants, O_2 may cause changes in breathing patterns and retinopathy in subjects at risk²

Sulfur Hexafluoride (SF_6)



Wash-in

SF_6 until equilibrium is reached at a known gas concentration¹

Washout

Subjects breathe room air¹

Limitation

Potent greenhouse gas – access is limited¹

1. Subbarao P, et al. *Ann Am Thorac Soc.* 2015;12(6):932-939. 2. Schultze SM, Frey U. *Eur Respir J.* 2013;41(3):500-502.

Strengths and Limitations of LCI

Strengths

- Sensitive to early airway disease before noticeable FEV₁ decline^{1,2}
- Requires only passive tidal breathing (vs forceful exhalation)²
- Can be performed in infants and young children without the need for sedation and mechanical manipulation^{2,3}
- Correlates with HRCT detection of lung structural changes⁴
- Correlates with risk for pulmonary exacerbation in patients with CF⁵
- Worsens with FEV₁ decline in patients with early and moderate lung disease⁶

Limitations

- Few centers have incorporated MBW into routine clinical practice⁷
- Longitudinal data are limited⁷
- Lack of guidelines and normative data to assist with interpreting results⁷
- Limited standardization for staff training, equipment, and analysis software⁷
- Minimum clinically important difference not yet established⁸
- Not practical for patients with advanced lung disease (ppFEV₁ <60) due to profound ventilation heterogeneity and extended wash-in and washout periods⁸

HRCT, high-resolution computed tomography.

1. Aurora P, et al. *Thorax*. 2004;59(12):1068-1073. 2. Robinson PD, et al. *Eur Respir J*. 2013;41(3):507-522. 3. Lum S, et al. *Thorax*. 2007;62(4):341-347. 4. Ellemunter H, et al. *Respir Med*. 2010;104(12):1834-1842. 5. Vermeulen F, et al. *Thorax*. 2014;69(1):39-45. 6. Kraemer R, et al. *Am J Respir Crit Care Med*. 2005;171(4):371-378. 7. Subbarao P, et al. *Ann Am Thorac Soc*. 2015;12(6):932-939. 8. Horsley A, Siddiqui S. *Respirology*. 2015;20(1):33-45.



LCI as an Outcome Measure in CF

Discriminating between disease and health

Detecting early lung disease

Tracking early disease progression

Correlations with lung imaging modalities

Correlations with local and systemic inflammatory markers

Correlation with risk for pulmonary exacerbations



LCI as an Outcome Measure in CF

Discriminating between disease and health
Detecting early lung disease
Tracking early disease progression



LCI Discriminates Between CF and Healthy Controls

Author	CF, Non-CF (n)	Subjects	LCI Results ¹
Hoo	71, 54	Infants	$P=0.002$
Lum	39, 21	Infants	$P<0.001$
Belessis	47, 25	Infants and children	$P<0.001$
Belessis	30, 25	Infants and children	$P<0.001$
Aurora	48, 45	Preschool	$P<0.001$
Singer	73, 50	Children	$P<0.001$
Amin	17, 28	Children	$P<0.001$
Keen	45, 35	Children	$P<0.001$
Aurora	22, 33	Children	$P<0.001$
Aurora	30, 30	Children	$P<0.001$
Owens	56, 52	Children	$P<0.001$
Gustafsson	43, 28	Children (<18 y)	$P<0.001$
Pittman	5, 10	Children	$P=NS$
Fuchs	68, 38	Children	$P<0.001$
Horsley	18, 29	Children	$P=0.022$
Bakker	15, 15	Children	$P<0.001$
Fuchs	26, 22	Children (<18 y)	$P<0.001$
Fuchs	10, 8	Children (<10 y)	$P=0.009$
Fuchs	139, 102	Children and adults	$P<0.001$
Gustafsson	18, 25	Adults	$P<0.001$
Verbanck	25, 25	Adults	$P<0.001$
Horsley	22, 17	Adults	$P<0.0001$
Horsley	33, 48	Adults	$P<0.001$


- The European Cystic Fibrosis Society Clinical Trial Network Standardization Committee undertook a review of LCI as a clinical endpoint¹
- They found that, overall, 22 out of 23 studies demonstrated the ability of LCI to discriminate between individuals with CF and healthy, non-CF subjects¹
- The 23rd study did not reach statistical significance due to suspended enrollment with a low number of participants after experiencing complications associated with the MBW device²

1. Kent L, et al. *J Cyst Fibros*. 2014;13(2):123-138. 2. Pittman JE, et al. *Pediatr Pulmonol*. 2012;47(12):1242-1250.

LCI Discriminates Between CF and Healthy Controls (cont)

Mean LCI values of patients with CF across multiple studies

Age Range	LCI
11-44 years	15 ¹
>10 years	14.6 ²
8-17 years	14.0 ¹
5-19 years	13.7 ¹
17-49 years	13.1 ³
9-20 years	12.8 ¹
7-18 years	12.4 ¹
12-56 years	11.9 ¹
6-16 years	11.53 ⁴
8-18 years	10.1 ⁵
8-17 years	9.9 ¹
41.4 (22.0) weeks	8.4 ⁶



- Common range in healthy individuals is from 5 to 9
 - Normal values relatively consistent from infancy to adulthood⁸
- Higher values indicate worse lung function⁹
 - Patients with CF have a wide range of LCI depending on severity of disease

ULN LCI values of controls across multiple studies

LCI	Age Range
8.2	4.5 (1.4) weeks ⁷
8.0	5.1 (0.8) weeks ⁷
7.8	19-58 years ³
7.7	2-6 years ⁷
7.5	5-16 years ⁷
7.3	6-16 years ⁷
7.1	4-18 years ⁷
7.1	6-16 years ³
7.0	5-20 years ⁷


ULN, upper limit of normal.

1. Sonneveld N, et al. *ERJ Express*. 2015;46(4):1055-1064. 2. Horsley AR, et al. *Thorax*. 2013;68(6):532-539. 3. Horsley AR, et al. *Thorax*. 2008;63(2):135-140. 4. Aurora P, et al. *Thorax*. 2004;59(12):1068-1073. 5. Robinson PD, et al. *Pediatr Pulmonol*. 2009;44(8):733-742. 6. Lum S, et al. *Thorax*. 2007;62(4):341-347. 7. Fuchs SI, et al. *Paediatr Respir Rev*. 2011;12(4):264-270. 8. Lum, S et al. *Eur Respir J*. 2013;41(6):1371-1377. 9. Horsley A. *Respir Med*. 2009;103(6):793-799.



LCI Detects Early Airway Disease in CF

In Infants



- Measurements obtained in 39 infants with CF and 21 healthy controls
- MBW performed during quiet sleep, before forced expiratory maneuvers
- LCI was significantly increased in CF vs healthy controls

Measure	CF (n=39)	Healthy Controls (n=21)
Age, weeks, mean (SD)	41.4 (22.0)	37.0 (15.1)
LCI, mean (SD)	8.4 (1.5)	7.2 (0.3)
LCI >7.8 ^a n (%)	22 (56.4)	0



Lum S et al. *Thorax*. 2007;62(4):341-347. Reprinted with permission.

^a7.8 was set as the ULN LCI based on the mean LCI in healthy controls of 7.2 (0.3).
Lum S, et al. *Thorax*. 2007;62(4):341-347.



LCI Detects Early Airway Disease in CF

In Preschool Age Children



Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Aurora P et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. *Am J Respir Crit Care Med.* 2005;171(3):249-256. The *American Journal of Respiratory and Critical Care Medicine* is an official journal of the American Thoracic Society.


- Measurements obtained in 30 children with CF (aged 2-5 years) and 30 age-matched healthy controls
- Results suggest that LCI is superior to spirometry at detecting abnormal lung function in children aged 2-5 years with CF
 - LCI identified abnormal lung function in a higher proportion of children with CF than spirometry (73% vs 13%)
 - LCI was superior to FEV_{0.5} z-score at identifying children infected with *Pseudomonas aeruginosa*

Horizontal lines show upper and lower limits of normal. FEV_{0.5} z-scores were calculated from reference equations published by Nystad et al, 2002. Aurora P, et al. *Am J Respir Crit Care Med.* 2005;171:249.



LCI Detects Early Airway Disease in CF

In Children Before Noticeable FEV₁ Decline




Aurora P et al. *Thorax*. 2004;59(12):1068-1073. Reprinted with permission,

- Measurements obtained in 22 children (aged 6-16 years) with CF and 33 healthy controls
- Results suggest that LCI is superior to spirometry at detecting irregular lung function in children with CF, identifying abnormalities in 95% of children vs the 50% identified with spirometry

*FEV₁ results were converted into standard deviation scores (z-scores) using published reference data from Rosenthal M (*Thorax*, 1993) and Freeman JV (*Arch Dis Child*, 1995), with a z-score of less than -1.96 being categorized as abnormal.
Aurora P, et al. *Thorax*. 2004;59(12):1068-1073.


Utilizing LCI to Track Lung Disease Progression In Preschool Age Children With CF



Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Stanojevic S et al. Progression of lung disease in preschool patients with cystic fibrosis. *Am J Respir Crit Care Med.* 2017;195(9):1216-1225. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.

- Data were collected on 156 participants aged 2.5 to 6 years with 800 LCI measurements (78 with CF, 78 age-matched healthy controls)
- The LCI worsened during cough episodes as well as pulmonary exacerbations in children with CF, whereas similar symptoms in healthy children did not impact LCI values
- Results suggest that while both LCI and spirometry discriminated health from disease, only the LCI identified significant deterioration of lung function in CF over time (figure above)

Utilizing LCI to Track Lung Disease Progression In Preschool Age Children to Adulthood



- Data based on serial lung function measurements performed in 142 children with CF, aged 6 to 20 years
- LCI z-score inversely associated with FEV₁ z-score (figure)
- Results suggest that LCI is more sensitive than spirometry at detecting early disease progression in this population

Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Kraemer R et al. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. *Am J Respir Crit Care Med.* 2005;171(4):371-378. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society. Kraemer R, et al. *Am J Respir Crit Care Med.* 2005;171(4):371-378.



LCI as an Outcome Measure


LCI correlates with lung imaging modalities



LCI Correlates With Lung Imaging Techniques

Computed Chest Tomography

- Thirty-four patients with CF (aged 6-26 years) with ppFEV₁ >80 were analyzed by MBW and CT
- Abnormal LCI z-scores and CT scores correlated significantly in 82.3% of subjects
- Structural changes (assessed by CT) were unlikely if LCI was normal (figure)
- Results suggest that diagnostic accuracy of LCI for detecting lung disease in patients with normal ppFEV₁ is good based on CT comparison



Reprinted from *Respiratory Medicine*, 104(12), Ellemunter H et al, Sensitivity of lung clearance index and chest computed tomography in early CF lung disease, 1834-1842, Copyright 2010, with permission from Elsevier.

LLN for CT score > 23.

ULN for LCI = 2.


Average annual ppFEV₁ >80 with at least 4 measurements per year was the cutoff used to screen patients in the center database for eligibility. FEV₁ in the study was reported as a z-score.

Ellemunter H, et al. *Respir Med*. 2010;104(12):1834-1842.



LCI Correlates With Lung Imaging Techniques

High Resolution Computed Chest Tomography



Gustafsson PM et al. *Thorax*. 2008;63(2):129-134. Reprinted with permission.


LLN, lower limit of normal; R_s, Spearman rank correlation coefficient.
The Brody scoring system was used in this study
Gustafsson PM, et al. *Thorax*. 2008;63(2):129-134.

- Forty-four patients with CF (aged 5-19 years) with ppFEV₁ ranging from 44% to 127% were analyzed by MBW, spirometry, and HRCT
- LCI correlated better with HRCT scores (R_s +0.85) than did FEV₁ (-0.62)
- LCI is more sensitive than FEV₁ for detecting structural lung disease in CF
- A normal LCI almost excludes HRCT abnormalities (figure, green box)
- Authors suggest that in some patients LCI may be even more sensitive than HRCT for detecting lung involvement in CF (figure, orange box)



LCI Correlates With Lung Imaging Techniques

High Resolution Computed Chest Tomography (cont)




(Brody II Scoring System)

Owens CM et al. *Thorax*. 2011;66(6):481-488. Reprinted with permission.

- Data were collected in 60 clinically stable children with CF (mean [SD] age 7.8 [1.3] years) and mean (SD) ppFEV₁ of 81.6 (18.3)
- Total CT score correlated more strongly with LCI (Spearman correlation = 0.77) than with spirometry (R = -0.43) or any other marker of lung function
- In addition to the relation with total CT score, LCI was significantly related to all individual elements except the parenchyma score (figure, parenchyma score data not shown)
- Results suggest that LCI and HRCT exhibit similar sensitivity to detect CF lung disease in this population

LCI Correlates With Lung Imaging Techniques


Hyperpolarized ^{129}Xe -MRI



- Eighteen participants (aged 8-17 years): 10 clinically stable patients with CF and 8 healthy age-matched volunteers with mean (SD) ppFEV₁ at baseline of 84 (14) and 101 (18), respectively
- A significant and strong correlation was observed between VDP and LCI for all subjects ($R^2=0.88$, $P<0.0001$)

LCI Correlates With Lung Imaging Techniques

T1 MRI ± Contrast, T2 MRI, and Perfusion MRI



Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Stahl M et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. *Am J Respir Crit Care Med*. 2017;195(3):349-359. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.

- Sixty-six clinically stable children with CF and mean (SD) age 11.9 (4.4) years and ppFEV₁ 83.1 (24.1), plus 25 children with CF and pulmonary exacerbation, age 13.9 (4.5) years and ppFEV₁ 65.4 (22.1)
- LCI showed strong correlations with the MRI morphology score ($r = 0.80$), and subscores for wall thickening/bronchiectasis ($r = 0.68$), mucus plugging ($r = 0.77$), abnormal perfusion ($r = 0.74$), and the MRI global score ($r = 0.84$)
- MRI provides additional information on the nature and regional distribution of abnormalities that contribute to ventilation inhomogeneity in different disease settings

MRI, magnetic resonance imaging.

Source of reference equation for baseline ppFEV₁ was not specified.

Stahl M, et al. *Am J Respir Crit Care Med*. 2017;195(3):349-359.



LCI as an Outcome Measure




Correlations with local and systemic inflammatory markers

Correlation with risk for pulmonary exacerbations



LCI Correlates With Early CF Inflammation and Infection

Pseudomonas Colonization and Inflammatory Markers in the BAL



Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Belessis Y et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. *Am J Respir Crit Care Med.* 2012;185(8):862-873. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.



- Forty-seven children with CF (mean [SD] age 1.55 [0.76] years) and 25 healthy children (mean [SD] age 1.26 [0.69] years) had technically acceptable LCI data
- LCI was significantly higher in infants and children with *P. aeruginosa* compared with children with CF without *P. aeruginosa* ($P=0.083$, left figure)
- LCI correlated with BAL IL-8 ($R^2=0.20$, $P=0.004$) and neutrophil count ($R^2=0.21$, $P=0.001$)
- An LCI below the ULN had a high negative predictive value (93%) in excluding *Pseudomonas*

BAL, bronchoalveolar lavage.
Belessis Y, et al. *Am J Respir Crit Care Med.* 2012;185(8):862-873.



LCI Correlates With Early CF Inflammation

Inflammatory Markers in Peripheral Blood



Reprinted with permission from Stuart Elborn, MD, Queen's University Belfast, Belfast, Northern Ireland.

- Data collected from 83 stable patients with CF with mean (SD) age 23.1 (14.6) years and ppFEV₁ 77.8 (19.8)
- LCI significantly correlated with CRP and white blood cell counts
- ppFEV₁ significantly correlated with CRP and white blood cell counts


CRP, C-reactive protein.

Source of reference equation for baseline ppFEV₁ was not specified.

Elborn SJ, et al. *Eur Respir J*. 2014;44(Suppl 58):P1206.



LCI Predicts Risk for Pulmonary Exacerbations



- Sixty-three patients with CF aged 5 to 19 years (median 12.4 years) prospectively followed for 1 year
- Twenty-six patients (41%) experienced 48 PEXs
- Baseline LCI z-score (figure, black arrow) was more sensitive than FEV₁ z-score (figure, grey arrow) to predict the occurrence of a PEX over 12 months, especially in the subgroup of patients (n=53) with normal FEV₁ z-score

PEX, pulmonary exacerbation.

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; †FEV₁ z-score lower than -2 was considered abnormal.


FEV₁ was expressed as the percent predicted or as z-scores using reference equations from the Global Lung Function Initiative.

Vermeulen F, et al. *Thorax*. 2014;69(1):39-45.



LCI Correlates With Pulmonary Exacerbations

Pulmonary Exacerbations and Post-Treatment Resolution



- Twenty-five children with CF, mean (SD) age 13.9 (4.5) years and ppFEV₁ 65.4 (22.1)
- Baseline assessments in clinically stable condition were done 3 to 6 months before PEx
- At the time of PEx, mean absolute LCI was significantly increased by 2 units (>10%; $P<0.001$) and returned to baseline at short-term follow-up after antibiotic therapy


* $P<0.001$ compared with stable CF N₂ group.

Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Stahl M et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. *Am J Respir Crit Care Med.* 2017;195(3):349-359. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society. Stahl M, et al. *Am J Respir Crit Care Med.* 2017;195(3):349-359.



LCI Correlates With Pulmonary Exacerbations

Pulmonary Exacerbations and Post-Treatment Resolution (cont)



- Data from 6 published and one unpublished study representing 176 PEx events from 5 pediatric datasets, two with both adult and pediatric data, median age 15 years (range: 5-56)
- Overall LCI decreased by 0.40 units (95% CI, -0.60 to -0.19; $P=0.004$) or 2.5% following treatment with IV antibiotics, but effect size was small
- Relative changes in LCI and ppFEV₁ were significantly correlated, but were discordant in 42.5% of subjects
- Minimum clinically important difference in LCI has yet to be defined

Sonneveld N et al. *Eur Respir J.* 2015;46(4):1055-1064. Reprinted with permission.

Univariate predictors of LCI change following 2 weeks of IV antibiotic treatment. For continuous variables (age, day 0 LCI, day 0 ppFEV₁, treatment duration, and nutritional z-scores), results correspond to the average LCI change following treatment for each 1-unit increase in each continuous variable

BMI, body mass index; CFRD, cystic fibrosis-related diabetes.

*Calculated for pediatric patients only.

Sonneveld N, et al. *Eur Respir J.* 2015;46(4):1055-1064.




The Use of LCI as an Outcome Measure in CF Interventional Clinical Trials



LCI as an Outcome in CF Therapeutic Trials

Trial Designs




1. Amin R, et al. *Thorax*. 2010;65(5):379-383. 2. Amin, R et al. *Eur Resp J*. 2011;37(4):806-812. 3. Subbarao P, et al. *Am J Respir Crit Care Med*. 2013;188(4):456-460.



LCI as an Outcome in CF Therapeutic Trials

Results

- Data from three trials evaluating impact of 4- or 48-week hypertonic saline (HS) or dornase alpha treatment¹⁻³
- Both agents demonstrated statistically significant impacts on reducing LCI¹⁻³
- Treatment effects ranged from 0.9 to 2.01¹⁻³



Reference	N	Treatment	Age Range	Treatment Effect on LCI	P Value
Amin 2010 ¹	20	Hypertonic saline	6-18 years (Mean ±SD: 10.5±3.1)	1.16±0.94 (95% CI, 0.27-2.05)	0.016
Amin 2011 ²	17	Dornase alfa	6-18 years (Mean ±SD: 10.32±3.35)	0.90±1.44	0.022
Subbarao 2013 ³	25	Hypertonic saline	<6 years (Median [range]: 2.6 [0.34-4.95])	2.01 (95% CI, 0.26-3.76)	0.025

SAFETY

- Adverse events were more frequent with hypertonic saline than with isotonic saline, including increased sputum production, fever, rhinorrhea, malaise, and cough¹
- Adverse events reported more frequently with dornase alpha than with placebo were cough (new or increased), pulmonary exacerbation, and dry throat²
- No serious adverse events were reported in either study^{1,2}

1. Amin R, et al. *Thorax*. 2010;65(5):379-383; 2. Amin, R et al. *Eur Resp J*. 2011;37(4):806-812. 3. Subbarao P, et al. *Am J Respir Crit Care Med*. 2013;188(4):456-460.



Interventional Clinical Trials With LCI as an Outcome Measure Currently Listed on ClinicalTrials.gov

- 21 clinical trials listed in total; 3 have been terminated and 1 has an unknown status
- Of the remaining 17 trials, 10 are interventional clinical trials

Evaluating the Clinical Significance of LCI Outcomes

- A minimum clinically significant difference has yet to be established for LCI¹
- Consensus statements suggest that treatment effect may be considered clinically significant if it is larger than the difference in LCI measurements observed between repeat measurements without intervention or change in clinical status (ie, “Coefficient of Repeatability” or “Coefficient of Reliability for Replicate Measures”)^{1,2}
- The Coefficient of Repeatability for the MBW assay using nitrogen gas and a commercial device is 0.6 in healthy children and 0.96 in children with CF³
- Coefficient of variation ($CV = SD / \text{mean} \times 100$) expressed as a percentage is also used as a measure of within-test and occasionally between-test repeatability,^{2,4,5} and a $CV > 10\%$ may suggest lack of reliability²
- Another variable that is often considered when evaluating the clinical significance of LCI results is how closely they compare with outcomes obtained for drugs known to be efficacious in CF¹
- Finally, and similar to any outcome measure, an evaluation of clinical significance should take into account trial design, treatment duration, and sustainability of effect^{1,6}

Summary

- LCI is sensitive to early airway disease before noticeable ppFEV₁ decline
- LCI can be performed in infants and young children without the need for sedation and mechanical manipulation
- LCI values have been demonstrated to correlate with
 - Spirometry measures including ppFEV₁
 - Lung disease progression
 - Imaging modalities such as HRCT and MRI
 - Inflammatory markers in the BAL such as bacterial colonization, IL-8, CRP, as well as neutrophil and white blood cell counts
- LCI has been evaluated as an outcome measure in several trials in CF, demonstrating significant treatment effects with agents such as dornase alfa and hypertonic saline
- The magnitude of response defined as “clinically significant” must still be established
- LCI is poised to become a valuable tool in the clinic to monitor early-stage CF lung disease, pending validated commercial equipment and standardization of procedures



Backup



Variables That Impact LCI Results




Variables That Impact LCI Results

- Tracer gas selection
- Equipment used
- Timing of physiotherapy
- Body position of the patient

Tracer Gas Selection

Nitrogen (N_2)



Wash-in

None (N_2 present in the lungs)¹


Washout

Subjects breathe 100% oxygen (O_2)¹

Limitation

In infants, O_2 may cause changes in breathing patterns and retinopathy in subjects at risk²

Sulfur Hexafluoride (SF_6)



Wash-in

SF_6 until equilibrium is reached at a known gas concentration¹

Washout

Subjects breathe room air¹


Limitation

Potent greenhouse gas – access is limited¹

1. Subbarao P, et al. *Ann Am Thorac Soc.* 2015;12(6):932-939. 2. Schultze SM, Frey U. *Eur Respir J.* 2013;41(3):500-502.

Tracer Gas Selection


N₂ produces disproportionately higher results in CF vs healthy controls



Reprinted from *PLoS One*, 8(2), Jensen R et al, Multiple breath nitrogen washout: a feasible alternative to mass spectrometry, e56868, Copyright 2013.

- On average, N₂ generates higher LCI values than SF₆
- In CF, the difference between the N₂ and the SF₆ systems was double that in health with a clear bias toward higher LCI N₂ compared to LCI SF₆ at higher mean values of LCI


Equipment Used for MBW



- LCI can vary depending on equipment used^{1,2}
- N₂ MBW systems have a larger dead-space volume (total 58.2 mL) than SF₆ MBW systems (total 15.4 mL)¹
- Increased dead space results in higher LCI¹
- Consensus recommendations pertaining to equipment dead space²
 - A facemask is to be used with infants and preschoolers
 - A nose clip and mouthpiece is to be used with older subjects
 - Upper limits for equipment dead space are specified
- It has been suggested that an adjustment be made for equipment dead space when calculating LCI¹

Effect of the Timing of Physiotherapy on LCI

Unclear what the impact of physiotherapy is on LCI measurements




LCI before (pre) and after (post) physiotherapy in 18 patients with a decrease and 11 patients with an increase.

Reprinted from *Journal of Cystic Fibrosis*, 14(5), Pflieger A et al, Short-term effects of physiotherapy on ventilation inhomogeneity in cystic fibrosis patients with a wide range of lung disease severity, 627-631, Copyright 2015, with permission from Elsevier.

- The short-term effects of physiotherapy on LCI are unpredictable¹
- One study says that timing of physiotherapy does not change LCI,² while another suggests that the short-term impact is variable¹
- Researchers may reduce variability in LCI measurements by keeping the timing of physiotherapy in relation to MBW procedures consistent³

Effect of Body Position of the Patient During MBW on LCI


Body position impacts the pressure within peripheral airways



Upright

- LCI is predominantly generated by intraregional ventilation heterogeneities¹

- LCI is affected by body position^{1,2}
- Positional changes can impact LCI outcomes in certain situations
 - When comparing LCI in infants vs toddlers
 - When performing longitudinal studies where infants become toddlers



Supine

- Functional residual volume is decreased in the supine position²
- Ventilation heterogeneity is increased² and LCI includes an interregional component¹

1. Verbanck S, et al. *J Appl Physiol.* 2012;112(5):782-790. 2. Ramsey KA, et al. *J Cyst Fibros.* 2017 Feb 7. pii: S1569-1993(17)30020-6. doi: 10.1016/j.jcf.2017.01.013. [Epub ahead of print]